CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-05-19 | Lamond David Director | Purchase | +400 | $54.09 | $22K | 1,659,184 |
| 2020-05-19 | Lamond David Director | Purchase | +5,906 | $55.42 | $327K | 1,665,090 |
| 2020-05-19 | Lamond David Director | Purchase | +32,894 | $56.42 | $1.9M | 1,697,984 |
| 2020-05-15 | Lamond David Director | Purchase | +1,263 | $46.30 | $58K | 1,654,599 |
| 2020-05-15 | Lamond David Director | Purchase | +985 | $48.37 | $48K | 1,655,584 |
| 2020-05-15 | Lamond David Director | Purchase | +1,600 | $48.96 | $78K | 1,657,184 |
| 2020-05-15 | Lamond David Director | Purchase | +1,000 | $50.71 | $51K | 1,658,184 |
| 2020-05-15 | Lamond David Director | Purchase | +500 | $52.20 | $26K | 1,658,684 |
| 2020-05-15 | Lamond David Director | Purchase | +100 | $53.10 | $5K | 1,658,784 |
| 2020-05-14 | Holsinger Leslie Executive Vice President | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2020-05-14 | LOWE CHRISTOPHER P. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2020-05-14 | McDowell Caryn Gordon Chief Legal & Adm. Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2020-04-02 | Detke Michael J. Chief Medical Officer | Option exercise | +5,515 | $6.91 | $38K | 22,746 |
| 2020-04-02 | Detke Michael J. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −5,515 | 109,606 | ||
| 2020-02-10 | Lamond David Director | Grant or award | +30,000 | $50.00 | $1.5M | 1,653,336 |
| 2020-02-07 | Detke Michael J. Chief Medical Officer | Option exercise | +17,231 | $6.91 | $119K | 17,231 |
| 2020-02-07 | Detke Michael J. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −17,231 | 115,121 | ||
| 2020-02-06 | Detke Michael J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-02-06 | Gafric Kristen SVP, Legal & Administration | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-02-06 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 |
Page 15 of 18 · 350 trades